Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00218283 · ClinicalTrials.gov registry record · Phase 2
Nicotine Lozenge to Reduce Smokeless Tobacco Use
A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00218283 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 100 participants.
The verdict
NCT00218283, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
Smokeless tobacco (ST), which includes both chewing tobacco and snuff, has as many health risks associated with its use as cigarettes. While there are many treatment programs that focus on stopping tobacco use, there are no interventions that specifically focus on reducing tobacco use. This study will evaluate the effectiveness of nicotine lozenge at reducing tobacco use in ST users.
Interventions
- DRUG Nicotine Lozenge
- BEHAVIORAL Behavioral Counseling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00218283
The ClinicalTrials.gov registry entry for NCT00218283 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nicotine Lozenge is the first listed.
NCT00218283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00218283 about?
NCT00218283 is a clinical study titled "Nicotine Lozenge to Reduce Smokeless Tobacco Use". Smokeless tobacco (ST), which includes both chewing tobacco and snuff, has as many health risks associated with its use as cigarettes. While there are many treatment programs that focus on stopping tobacco use, there are no interventions that specifically focus on reducing tobacco use. This study wi...
What is the current status of trial NCT00218283?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2005-01. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00218283?
The interventions under investigation include: Nicotine Lozenge (DRUG), Behavioral Counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT00218283?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.